Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532869 | 0.86 | EGLN3 (0.50) | CYP3A4CYP2C9PKMYT1HPGDEGLN3 | |
| SCHEMBL3520781 | 0.85 | EGLN3 (0.38) | CYP3A4CYP2C9PKMYT1HPGDHSD17B10 | |
| SCHEMBL3521384 | 0.84 | CASP1 (0.49) | CYP3A4CYP2C9HPGDHSD17B10CASP1 | |
| SCHEMBL3753051 | 0.84 | MAPK1 (0.45) | HPGDHSD17B10EGLN3LMNAALDH1A1 | |
| SCHEMBL3532359 | 0.84 | LMNA (0.37) | CYP3A4CYP2C9PKMYT1HPGDHSD17B10 | |
| SCHEMBL3766990 | 0.84 | EGLN3 (0.38) | HPGDHSD17B10CASP1EGLN3LMNA | |
| SCHEMBL3518478 | 0.83 | EGLN3 (0.50) | HPGDHSD17B10CASP1EGLN3LMNA | |
| SCHEMBL3761570 | 0.83 | EGLN3 (0.45) | CYP3A4CYP2C9HPGDHSD17B10CASP1 | |
| SCHEMBL3516187 | 0.82 | HSD17B10 (0.46) | HPGDHSD17B10CASP1EGLN3LMNA | |
| SCHEMBL3759035 | 0.82 | CASP1 (0.40) | HPGDHSD17B10CASP1EGLN3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101983384-A | Prolyl hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2011-03-02 | — | — | CN | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | CYP3A4 824/4885CYP2C9 783/4885PKMYT1 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.